A recently conducted poll has found that most Americans support the study of substances such as MDMA and psilocybin as alternative options for mental health treatment for military service members. Bipartisan legislators championing for policy issues such as the promotion of research on psychedelics and the legalization of cannabis appear to have plenty of support from Americans, despite Congress receiving criticism for not aligning with its constituents on such matters.
The YouGov poll, which was conducted between July 22—25, 2022, found that nearly 55% of Americans were in favor of permitting studies into the therapeutic potential of a range of psychedelic substances for members of the military suffering from PTSD. This figure includes 54% of Independents, 45% of GOP members and 60% of Democrats. Of the total number of respondents, only 18% weren’t in favor of research on these substances proceeding.
The poll, which interviewed 1,000 individuals in America, also found that less than one-third of Americans supported the decriminalization of LSD, MDMA or psilocybin. This is despite the fact that various cities and more states have advanced/are advancing broader psychedelics reform.
This is in addition to finding that individuals who lived in the western part of the country. and with personal experiences using the substances were more likely to embrace such changes in policy.
With regard to marijuana reform, the poll found that measures to loosen laws on cannabis received more support from Democrats than Republicans. However, when it came to conducting research on investigative treatments for military members, the gap reduced. A defense measure that was recently approved by the House demonstrates this trend.
Rep. Dan Crenshaw and Rep. Alexandria Ocasio-Cortez sponsored research amendments that were included in next year’s National Defense Authorization Act, which cleared the House last month. Crenshaw championed for an amendment that would enable the Defense secretary to approve grants for research into the medical value of psychedelics, including DMT, ibogaine, psilocybin and MDMA for service members with post-traumatic stress disorder.
On the other hand, Occasion-Cortex’s proposal would require the Defense Department to conduct research on the potential of MDMA and psilocybin as alternatives to the use of opioids in treating traumatic brain injuries and PTSD.
These legislators have in the past showed interest in research on psychedelics, with bipartisan support on the issue extending to the Senate. In a recent interview, Sen. Lindsey Graham stated that he was open-minded about advancing measures on psychedelic research for military members.
This poll comes at a time when plenty of companies, including Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), are investing heavily into studying the medicinal attributes of various psychedelics such as psilocybin with a view to improving how various mental health conditions can be treated in the general population, including serving or retired military personnel.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
